• BioMarin agreed to buy Alesta Therapeutics for USD 275 million upfront, aiming to add lead asset ALE1 to its pipeline.
• Deal includes up to USD 215 million in milestone payments tied to development and regulatory progress.
• ALE1 is an oral small-molecule candidate for hypophosphatasia, now in a Phase 1/2a trial in healthy volunteers and adults.
• Alesta will spin out non-ALE1 assets before closing, leaving no Alesta employees transferring to BioMarin.
• BioMarin expects to fund the purchase with cash on hand, with a modestly dilutive impact on 2026 results excluding upfront consideration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608180830PR_NEWS_USPR_____SF28421) on August 18, 2026, and is solely responsible for the information contained therein.